Hint mode is switched on Switch off

Eton Pharmaceuticals, ordinary share
ETON, US29772L1089

Add a stock to WL
Choose all Reset all
Eton Pharmaceuticals, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical product using the U.S. Food and Drug Administration’s regulatory pathway. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products.
  • Issuer
  • Full borrower / issuer name
    Eton Pharmaceuticals, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ETON
  • Placement
    13.11.2018
  • Lock up period
    180
  • Number of papers
    3,600,000
  • Volume of raised funds
    21.6 mln USD
  • Placement share
    21.28%
  • Final placement price
    6 USD
  • Price change since placement date
    -100%
  • By capitalization
    101.51 mln USD
Other placements of the issuer
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ETON
  • Placement
    30.03.2020
  • Lock up period
    180
  • Number of papers
    600,000
  • Volume of raised funds
    2 mln USD
  • Placement share
    2.93%
  • Final placement price
    3.33 USD
  • Price change since placement date
    1,279.58%
  • By capitalization
    68.21 mln USD

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
III q eng
IV q eng
Show all Hide

Related Stock indices

Indicators

News

15/05/2026 Eton Pharmaceuticals (NASDAQ: ETON) Stock Analysis: H.C. Wainwright Boosts Price Target Amid Strong Performance
16/04/2026 Eton Pharmaceuticals: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Regulation Fd Disclosure, Financial Statements And Exhibits
09/04/2026 Eton Pharmaceuticals: Entry Into A Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant
27/02/2026 Eton Pharmaceuticals: Entry Into A Material Definite Agreement, Financial Statements And Exhibits
04/12/2025 Eton Pharmaceuticals: Regulation Fd Disclosure, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.